NORTH HAVEN, Conn.--(BUSINESS WIRE)--Covidien (NYSE: COV, BSX: COV), a leading global provider of healthcare products, today announced the launch of Permacol™ Biologic Implant, a biologic mesh for hernia repair. Permacol™, which joins the Company’s line of products following the acquisition of Tissue Science Laboratories, is available in the United States, Europe, Canada and Korea and will be registered in other markets starting in 2009.
